Cantor Fitzgerald Reiterates Buy Rating for Aerie Pharmaceuticals, Inc. (AERI)
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)‘s stock had its “buy” rating reaffirmed by stock analysts at Cantor Fitzgerald in a research report issued on Wednesday. They presently have a $62.00 price objective on the stock. Cantor Fitzgerald’s price objective suggests a potential downside of 1.51% from the company’s current price.
Other equities analysts have also issued research reports about the company. Canaccord Genuity set a $65.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 16th. HC Wainwright set a $69.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Stifel Nicolaus reiterated a “buy” rating and issued a $70.00 price target on shares of Aerie Pharmaceuticals in a research report on Friday, July 28th. Mizuho started coverage on Aerie Pharmaceuticals in a research report on Wednesday, September 6th. They issued a “buy” rating and a $70.00 price target for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price target on shares of Aerie Pharmaceuticals in a research report on Sunday, September 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $67.46.
Shares of Aerie Pharmaceuticals (NASDAQ:AERI) remained flat at $62.95 on Wednesday. 1,123,287 shares of the stock were exchanged. Aerie Pharmaceuticals has a 12 month low of $32.05 and a 12 month high of $65.89. The company’s 50-day moving average is $55.16 and its 200-day moving average is $50.69. The stock’s market cap is $2.29 billion.
Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.02. On average, equities research analysts predict that Aerie Pharmaceuticals will post ($2.59) earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Quantbot Technologies LP acquired a new stake in Aerie Pharmaceuticals during the 1st quarter worth about $107,000. Ameritas Investment Partners Inc. acquired a new stake in Aerie Pharmaceuticals during the 1st quarter worth about $108,000. BNP Paribas Arbitrage SA boosted its position in Aerie Pharmaceuticals by 2,711.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after acquiring an additional 3,579 shares during the period. Amalgamated Bank acquired a new stake in Aerie Pharmaceuticals during the 2nd quarter worth about $204,000. Finally, Palisade Capital Management LLC NJ acquired a new stake in Aerie Pharmaceuticals during the 2nd quarter worth about $212,000. Hedge funds and other institutional investors own 94.64% of the company’s stock.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.